{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:14:15Z","timestamp":1781946855630,"version":"3.54.5"},"reference-count":47,"publisher":"ALUNA","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>The aim: The aim of this research is to evaluate some immunological biomarkers in cases of Rheumatoid arthritis and to verify their correlation with activity of disease among the population of Thi-Qar province. \nMatherials and methods: This study included 45 cases of rheumatoid arthritis and 45 healthy subjects. All cases underwent complete history taking, thor\u00acough clinical examination, and laboratory tests including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Anti-citrulline antibody (Anti-CCP) and rheumatoid factor (RF). IL-17and TNF-\u03b1 blood level was measured by Enzyme Linked Immunosorbent Assay (ELISA) method. DAS-28 (Disease activity score 28) was evaluated. \nResults: Serum levels TNF-\u03b1 was higher in Rheumatoid arthritis patients (424.3\u00b119.46 pg\/ml) than in healthy individuals (112.7\u00b14.73 pg\/ml), and IL-17 blood levels were higher in Rheumatoid arthritis patients (233.5\u00b1241.4 pg\/ml) than the healthy individuals group (47.24\u00b149.7 pg\/ml). There was significant association found among IL-17, DAS-28, CRP and hemoglobin levels. \nConclusions: In conclusion, IL-17 blood levels were significantly increased in peoples with rheumatoid arthritis than in healthy individuals. Its significant relationship with DAS-28 suggested that the level of IL-17 in serum could be important immunological biomarker for activity of disease in disease of Rheumatoid arthritis.<\/jats:p>","DOI":"10.36740\/wlek202301111","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T11:13:07Z","timestamp":1678360387000},"page":"77-83","source":"Crossref","is-referenced-by-count":2,"title":["ASSOCIATION OF SOME IMMUNOLOGICAL BIOMARKERS WITH RHEUMATOID ARTHRITIS PATIENTS IN THI-QAR PROVINCE"],"prefix":"10.36740","volume":"76","author":[{"given":"Ghaneemah Malik","family":"Hamadi","sequence":"first","affiliation":[{"name":"SOUTHERN TECHNICAL UNIVERSITY, AL-NASIRIYA TECHNICAL INSTITUTE, AL-NASIRIYA, IRAQ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22436","published-online":{"date-parts":[[2023]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Brusca SB, Abramson SB, Scher JU. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheumatol. 2014;26(1):101-107.","DOI":"10.1097\/bor.0000000000000008"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Glick-Bauer M, Yeh MC. The health advantage of a vegan diet: exploring the gut microbiota connection. Nutrients. 2014;6(11):4822-4838.","DOI":"10.3390\/nu6114822"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.","DOI":"10.1056\/nejmra1004965"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Solus JF, Chung CP, Oeser A, et al. Genetics of serum concentration ofIL-6 and TNFalpha in systemic lupus Erythematous and rheumatoid arthritis: a candidate gene analysis. Clin Rheumatol. 2015;34(8):1375-1382.","DOI":"10.1007\/s10067-015-2881-6"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72(4):583-589.","DOI":"10.1136\/annrheumdis-2012-202470"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Hughes-Austin JM, Deane KD, Derber LA, et al. multiple cytokines and Chemokines are associated with rheumatoid arthritis-related autoimmunity in first degree relatives without rheumatoid arthritis: Studies of the Aetiology of Rheumatoid Arthritis (SERA). Ann Rheum Dis. 2013;72(6):901-907.","DOI":"10.1136\/annrheumdis-2012-201505"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Yang XK, Li P, Li S, Zhang C, Li BZ, Leng RX, Pan HF, Ye DQ. Genetic variant of IL-10RA and susceptibility to rheumatoid arthritis in a Chinese population. Clin Rheumatol. 2017;36(4):825-830.","DOI":"10.1007\/s10067-016-3449-9"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Chunlei T, Shu C, Hai Q, Wenlong H. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135(2):112-124.","DOI":"10.1111\/j.1365-2567.2011.03522.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Yao Z, Fanslow W, Seldin M, et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 1995;3(6):811-821.","DOI":"10.1016\/1074-7613(95)90070-5"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;11:763-76.","DOI":"10.1038\/nrd3794"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Beringer A, Noack M, Miossec P. IL-17 in Chronic Inflammation: From Discovery to Targeting. Trends Mol Med. 2016;22:230-41.","DOI":"10.1016\/j.molmed.2016.01.001"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023-38.","DOI":"10.1016\/S0140-6736(16)30173-8"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Hot A, Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis. 2011;70:727-32.","DOI":"10.1136\/ard.2010.143768"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Ndongo-Thiam N, Miossec P. A cell-based bioassay for circulating bioactive IL-17: application to destruction in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1629-31.","DOI":"10.1136\/annrheumdis-2014-207110"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205-19.","DOI":"10.1056\/NEJMra1004965"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine. 2000;12:1092-9.","DOI":"10.1006\/cyto.2000.0681"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 2001;3:168-77.","DOI":"10.1186\/ar294"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Alam J, Jantan I, Bukhari SN: Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother. 2017;92:615-33.","DOI":"10.1016\/j.biopha.2017.05.055"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C: Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis. 1990;49:665-7.","DOI":"10.1136\/ard.49.9.665"},{"key":"ref19","unstructured":"20. Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care. 2012;18(13 Suppl):S295-302."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Shrivastava AK, Singh HV, Raizada A, et al. Inflammatory markers in patients with rheumatoid arthritis. Allergol Immunopathol (Madr). 2015;43:81-7.","DOI":"10.1016\/j.aller.2013.11.003"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Cunnane G, Fitzgerald O, Beeton C, Cawston TE, Bresnihan B. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinase 1 in rheumatoid arthritis. Arthritis Rheum. 2001;44:2263-74.","DOI":"10.1002\/1529-0131(200110)44:10<2263::AID-ART389>3.0.CO;2-1"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Hess A, Axmann R, Rech J, et al. Blockade of TNF-\u03b1 rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A. 2011;108:3731-6. doi: 10.1073\/pnas.1011774108","DOI":"10.1073\/pnas.1011774108"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Farrugia M, Baron B. The role of TNF-\u03b1 in rheumatoid arthritis: a focus on regulatory T cells. J Clin Transl Res. 2016;2:84-90.","DOI":"10.18053\/jctres.02.201603.005"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Harre U, Schett G. Cellular and molecular pathways of structural damage in rheumatoid arthritis. Semin Immunopathol. 2017; 39: 355-63.","DOI":"10.1007\/s00281-017-0634-0"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Sikorska D, Kawka E, Rutkowski R, Samborski W, Witowski J. The intensity of joint pain in relation to changes in serum TNF\u03b1 during therapy with anti-TNF\u03b1 inhibitors. Inflammopharmacology. 2019;27:679-83.","DOI":"10.1007\/s10787-019-00564-x"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development, validation in a prospective longitudinal study of cases with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8.","DOI":"10.1002\/art.1780380107"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Aletaha D, Neogi T, Silman A, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.","DOI":"10.1002\/art.27583"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29. Christodoulou C, Choy EH. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med. 2006;6:13-9.","DOI":"10.1007\/s10238-006-0088-5"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Lubberts E, Koenders MI, van den Berg WB. The role of T cellinterleukin-17 in conducting destructive arthritis: Lessons from animal models. Arthritis Res Ther. 2005;7:29-37.","DOI":"10.1186\/ar1072"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Sokka T, Hakkinen A, Krishnan E, Hannonen P. Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Ann Rheum Dis. 2004;63:494-497.","DOI":"10.1136\/ard.2003.009530"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Widdifield j, Paterson J, Bernatsky M, et al. The Rising Burden of Rheumatoid Arthritis Surpasses Rheumatology Supply Canadian Public Health Association. J Public Health. 2013;104(7):e450-e455.","DOI":"10.17269\/cjph.104.4115"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Gonzalez A, Maradit KH, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56:3583-7.","DOI":"10.1002\/art.22979"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Qin B, Yang M, Fu H, et al. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis Arthritis Res Ther. 2015;17:86.","DOI":"10.1186\/s13075-015-0745-8"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. Lu B, Hiraki LT, Sparks JA, et al. being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis. 2014;73:1914-22.","DOI":"10.1136\/annrheumdis-2014-205459"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. de Almeida PH, Pontes TB, Matheus JP, Muniz LF, da Mota LM. Occupational therapy in rheumatoid arthritis: what rheumatologists need to know. Rev Bras Reumatol. 2015;55(3):272-280","DOI":"10.1016\/j.rbre.2014.07.008"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37. Metawi S, Abbas D, Kamal M, Ibrahim M. Serum, synovial fluid levels ofinterleukin-17 in correlation with disease activity in cases with RA. Clin Rheumatol. 2011;30:1201-1207.","DOI":"10.1007\/s10067-011-1737-y"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38. Theyagarajan R, Sivasankari U, Sudhakar T, Suresh S, Saketharaman P, Ahamed N. Comparison of serum tumor necrosis factor-\u03b1 levels in rheumatoid arthritis individuals with and without chronic periodontitis: A biochemical study. J Indian Soc Periodontal. 2018;22(2):116-121.","DOI":"10.4103\/jisp.jisp_362_17"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39. Delima AJ, Oates T, Assuma R, et al. Soluble antagonists to interleukin-1 (IL-1) and tumor necrosis factor (TNF) inhibits loss of tissue attachment in experimental periodontitis. J Clin Periodontol. 2001;28:233-40.","DOI":"10.1034\/j.1600-051x.2001.028003233.x"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40. Nordahl S, Alstergren P, Kopp S. Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. J Oral Maxillofac Surg. 2000;58:525-30.","DOI":"10.1016\/s0278-2391(00)90015-6"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41. van Amelsfort JM, van Roon JA, Noordegraaf M, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. Proinflammatory media-tor-induced reversal of CD4+, CD25+ regulatory T cell-med-iated suppression in rheumatoid arthritis. Arthritis Rheum. 2007;56:732-742.","DOI":"10.1002\/art.22414"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42. Dhaouadi T, Chahbi M, Haouami Y, Sfar I, et al. IL-17A, IL-17RC polymorphisms, IL17 plasma levels in Tunisian cases with rheumatoid arthritis. Plos One. 2018;13 (3):194-201.","DOI":"10.1371\/journal.pone.0194883"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43. Melis L, Vandooren B, Kruithof E, et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis. 2010;69(3):618-623.","DOI":"10.1136\/ard.2009.107649"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44. Lee Y, Bae S. Associations between circulating IL-17 levels, rheumatoid arthritis & between IL-17 gene polymorphisms, disease susceptibility: a meta-analysis. Postgrad Med J. 2017;93(1102):465-471.","DOI":"10.1136\/postgradmedj-2016-134637"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45. Mahabir V, Ross C, Popovic S, et al. A blinded study of bone marrow examinations in cases with primary immune thrombocytopenia. Eur J Haematol. 2013;90(2):121-126.","DOI":"10.1111\/ejh.12041"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46. Al-Saadany H, Hussein M, Gaber R, Zaytoun H. Th-17 cells, serum IL-17 in rheumatoid arthritis cases; Correlation with disease activity. The Egyptian Rheumatologist. 2016;38(1):1-7.","DOI":"10.1016\/j.ejr.2015.01.001"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47. Pavlovic V, Dimic A, Milenkovic S, Krtinic D. Serum levels of IL-17, IL-4, TNF-\u03b1 in Serbian case with early rheumatoid arthritis. J Res Med Sci. 2014;19(1):18-22.","DOI":"10.1515\/med-2015-0019"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T10:00:23Z","timestamp":1688119223000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2023\/WiadLek2023i1.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023]]},"published-print":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202301111","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}